key: cord-0962121-afm46yds authors: Altarawneh, H. N.; Chemaitelly, H.; Ayoub, H.; Tang, P.; Hasan, M. R.; YASSINE, H. M.; Al-Khatib, H. A.; Smatti, M. K.; Coyle, P.; Al-Kanaani, Z.; Al-Kuwari, E.; Jeremijenko, A.; Kaleeckal, A. H.; Latif, A. N.; Shaik, R. M.; Abdul-Rahim, H. F.; Nasrallah, G.; Al-Kuwari, M. G.; Butt, A. A.; Al-Romaihi, H. E.; Al-Thani, M. H.; Al-Khal, A.; Bertollini, R.; Abu-Raddad, L. J. title: Effect of prior infection, vaccination, and hybrid immunity against symptomatic BA.1 and BA.2 Omicron infections and severe COVID-19 in Qatar date: 2022-03-22 journal: nan DOI: 10.1101/2022.03.22.22272745 sha: cde8dfb45ffa161d812a3a4b226ebc57035ce0f0 doc_id: 962121 cord_uid: afm46yds BACKGROUND: Protection offered by five different forms of immunity, combining natural and vaccine immunity, was investigated against SARS-CoV-2 Omicron symptomatic BA.1 infection, symptomatic BA.2 infection, BA.1 hospitalization and death, and BA.2 hospitalization and death, in Qatar, between December 23, 2021 and February 21, 2022. METHODS: Six national, matched, test-negative case-control studies were conducted to estimate effectiveness of BNT162b2 (Pfizer-BioNTech) vaccine, mRNA-1273 (Moderna) vaccine, natural immunity due to prior infection with pre-Omicron variants, and hybrid immunity from prior infection and vaccination. RESULTS: Effectiveness of only prior infection against symptomatic BA.2 infection was 46.1% (95% CI: 39.5-51.9%). Effectiveness of only two-dose BNT162b2 vaccination was negligible at -1.1% (95% CI: -7.1-4.6), but nearly all individuals had received their second dose several months earlier. Effectiveness of only three-dose BNT162b2 vaccination was 52.2% (95% CI: 48.1-55.9%). Effectiveness of hybrid immunity of prior infection and two-dose BNT162b2 vaccination was 55.1% (95% CI: 50.9-58.9%). Effectiveness of hybrid immunity of prior infection and three-dose BNT162b2 vaccination was 77.3% (95% CI: 72.4-81.4%). Meanwhile, prior infection, BNT162b2 vaccination, and hybrid immunity all showed strong effectiveness >70% against any severe, critical, or fatal COVID-19 due to BA.2 infection. Similar levels and patterns of effectiveness were observed for BA.1 and for the mRNA-1273 vaccine. CONCLUSIONS: There are no discernable differences in the effects of prior infection, vaccination, and hybrid immunity against BA.1 versus BA.2. Hybrid immunity resulting from prior infection and recent booster vaccination confers the strongest protection against either subvariant. Vaccination enhances protection of those with a prior infection. CoV-2-related data and associated demographic information, with no missing information, since pandemic onset, documenting all polymerase chain reaction (PCR) tests and more recently, rapid antigen tests conducted at healthcare facilities (from January 5, 2022 onward). Every PCR test (but not rapid antigen tests) conducted in Qatar is classified on the basis of symptoms and the reason for testing (clinical symptoms, contact tracing, surveys or random testing campaigns, individual requests, routine healthcare testing, pre-travel, at port of entry, or other). Qatar has unusually young, diverse demographics, in that only 9% of its residents are ≥50 years of age, and 89% are expatriates from over 150 countries. 12 Qatar launched its vaccination program at the end of December of 2020 using both the BNT162b2 and mRNA-1273 mRNA vaccines. 13 Nearly all individuals were vaccinated in Qatar, but if vaccinated elsewhere, those vaccinations were still recorded in the health system at the port of entry upon arrival in Qatar. Further descriptions of the study population and these national databases have been reported previously. 6, [12] [13] [14] [15] [16] [17] [18] [19] Two studies were conducted. In the first study, labeled as the BNT162b2-vaccine study, we estimated effectiveness of prior infection, BNT162b2 vaccination, and hybrid immunity of prior infection and BNT162b2 vaccination together against symptomatic BA.1 infection, symptomatic BA.2 infection, and any symptomatic Omicron infection due to either subvariant, using the testnegative, case-control study design, a standard design for assessing effectiveness of vaccination and prior infection. 3, 18, [20] [21] [22] [23] Effectiveness was also estimated against any severe, 10 critical, 10 or fatal 11 COVID-19. In the second study, labeled as the mRNA-1273-vaccine study, the same effectiveness measures were estimated, but with mRNA-1273 vaccination instead of BNT162b2 vaccination. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For estimation of effectiveness against symptomatic infection, we exact-matched cases (PCRpositive persons) and controls (PCR-negative persons) identified between December 23, 2021 and February 21, 2022, during the Omicron wave, 2-6 in a one-to-one ratio by sex, 10-year age group, nationality, and calendar week of PCR testing. Matching was done to control for known differences in the risk of exposure to SARS-CoV-2 infection in Qatar. 12, [24] [25] [26] [27] Matching by these factors was previously shown to provide adequate control of differences in the risk of infection exposure in Qatar, in studies of different epidemiologic designs and that included control groups, including test-negative case-control studies. 13, 14, 18, 28, 29 For estimation of effectiveness against any severe, 10 critical, 10 or fatal 11 COVID-19, we used a matching ratio of one-to-five to improve statistical precision of estimates. Only the first PCR-positive test during the study was included for each case, while all PCRnegative tests during the study were included for each control. Controls included individuals with no record of a PCR-positive test during the study period. Only PCR tests conducted for clinical suspicion among cases and controls, that is, due to symptoms compatible with a respiratory tract infection (symptomatic infection), were included in this analysis. SARS-CoV-2 reinfection is conventionally defined as a documented infection ≥90 days after an earlier infection, to avoid misclassification of prolonged PCR positivity as reinfection, if a shorter time interval is used. 3, 30, 31 Prior infection was thus defined as a PCR-positive test ≥90 days before this study's PCR test. Individuals with a PCR-positive test <90 days before the study's PCR test were excluded from both cases and controls. Accordingly, prior infections in this study were due to pre-Omicron variants, as they occurred prior to onset of the Omicron wave in Qatar. 2 Informed by viral genome sequencing and real-time reverse-transcription PCR (RT-qPCR) genotyping (further data are presented in Section S2), a SARS-CoV-2 infection with the Omicron BA.1 subvariant was proxied as an S-gene "target failure" (SGTF) case using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, USA) that tests for the S-gene and is affected by the del-69/70 mutation in the S-gene. 32 A SARS-CoV-2 infection with the BA.2 subvariant was proxied as a non-SGTF case, using this TaqPath Kit. Further details of laboratory methods for the RT-qPCR testing are found in Section S2. All PCR testing was conducted at the Hamad Medical Corporation Central Laboratory or at Sidra Medicine Laboratory, following standardized protocols. While all records of PCR testing in Qatar were examined for selection of cases and controls, only matched samples were analyzed. Cases and controls were described using frequency distributions and measures of central tendency, and compared using standardized mean differences (SMDs). An SMD was defined as the difference in the mean of a covariate between groups, divided by the pooled standard deviation, with values <0.1 indicating adequate matching. 33 Odds ratios, comparing odds of prior infection and/or vaccination among cases versus controls, and associated 95% confidence intervals (CIs) were derived using conditional logistic regression, factoring the matching in the study design. This analytical approach minimizes potential bias due to variation in epidemic phase, 20,34 roll-out of vaccination during the study, 20,34 or other All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. guidelines. The STROBE checklist can be found in Table S1 . Between (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. duration between the first and second doses was 28 days (IQR, 28-30 days), and between the second and booster doses was 236 days (IQR, 213-260 days) . Effectiveness against BA.1-the BNT162b2-vaccine study Figure 1 shows the process for selecting the study populations and Table 1 describes their characteristics. The study was based on the total population of Qatar; thus, the study population is broadly representative of the internationally diverse, but young and predominantly male, total population of Qatar (Table S2) . Effectiveness of only prior infection against symptomatic BA.1 infection was 50.2% (95% CI: 38.1-59.9%) ( Figure 2A and Table 2 ). The median duration between the prior infection and the PCR test was 324.5 days (IQR, 274-497 days). Effectiveness of only two-dose (primary series) BNT162b2 vaccination was negligible at -4.9% (95% CI: -16. 4-5.4) . The median duration between the second dose and the PCR test was 268 days (IQR, 211-293 days), well beyond the duration of protection of two-dose BNT162b2 vaccination against symptomatic Omicron infections. 5, 37 Effectiveness of only three-dose (booster) vaccination was 59.6% (95% CI: 52.9-65.3%). The median duration between the third dose and the PCR test was 42 days (IQR, 27-62 days). Effectiveness of hybrid immunity of prior infection and two-dose vaccination was 51.7% (95% CI: 43.5-58.7%), similar to effectiveness of only prior infection ( Figure 2A and Table 2 ). Effectiveness of hybrid immunity of prior infection and three-dose vaccination was highest at 74.4% (95% CI: 63.4-82.2%). Meanwhile, prior infection, vaccination, and hybrid immunity all showed strong effectiveness >90% against severe, critical, or fatal COVID-19 due to BA.1 infection, but some of the 95% CIs were wide or could not be estimated ( Figure 2B and Table 2 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 39.5-51.9%) ( Figure 2C and Table 2 ). The median duration between the prior infection and the PCR test was 319 days (IQR, 275-499 days). Effectiveness of only two-dose BNT162b2 vaccination was negligible at -1.1% (95% CI: -7.1-4.6). The median duration between the second dose and the PCR test was 270 days (IQR, 213-296 days), well beyond the duration of protection of two-dose BNT162b2 vaccination against symptomatic Omicron infections. 5, 37 Effectiveness of only three-dose vaccination was 52.2% (95% CI: 48.1-55.9%). The median duration between the third dose and the PCR test was 43 days (IQR, 26-65 days). Effectiveness of hybrid immunity of prior infection and two-dose vaccination was 55.1% (95% CI: 50.9-58.9%), similar to effectiveness of only prior infection ( Figure 2C and Table 2 ). Effectiveness of hybrid immunity of prior infection and three-dose vaccination was highest at 77.3% (95% CI: 72.4-81.4%). Meanwhile, prior infection, vaccination, and hybrid immunity all showed strong effectiveness >70% against severe, critical, or fatal COVID-19 due to BA.2 infection, but some of the 95% CIs were wide or could not be estimated ( Figure 2D and Table 2 ). Effectiveness of prior infection, BNT162b2 vaccination, and hybrid immunity against any symptomatic Omicron infection with either subvariant showed similar levels and patterns to those of effectiveness against BA.1 or BA.2 ( Figure 3A and Table 2 ). Effectiveness of prior infection, vaccination, and hybrid immunity against severe, critical, or fatal COVID-19 due to All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. any Omicron infection also showed similar levels and patterns to those of effectiveness against BA.1 and BA.2 ( Figure 3B and Table 2 ). Effectiveness against BA.1, BA.2, and any Omicron infection-the mRNA-1273-vaccine study Figure S2 shows the process for selecting the study populations and Table S3 describes their characteristics. The study population is broadly representative of the population of Qatar (Table S2 ). Effectiveness of prior infection, vaccination, and hybrid immunity in the mRNA-1273-vaccine study showed similar levels and patterns to those in the BNT162b2-vaccine study. This was true for effectiveness against BA.1, BA.2, and any Omicron infection, and against both symptomatic infection and severe, critical, or fatal COVID-19 ( Figure 4 for BA.1 and BA.2, Figure 3 for any Omicron, and Table S4 ). Prior infection with a pre-Omicron variant, nearly a year earlier, was associated with ~50% reduced risk of infection. There was no discernable difference in protection of prior infection against either BA.1 or BA.2. Meanwhile, two-dose vaccination had negligible effectiveness against either BA.1 or BA.2, but most individuals had received their second doses >8 months earlier. These findings are explained by the short-lived protection of primary-series vaccination against Omicron infections, 5,37 but more durable protection for natural infection. 3, 38 Booster vaccination was associated with ~60% reduced risk of infection. There was no discernable difference in protection of booster vaccination against either BA.1 or BA.2. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. However, most individuals had received their booster doses <45 days earlier, perhaps explaining the relatively high effectiveness. 5 Protection of hybrid immunity of prior infection and primary-series vaccination was similar to that of prior infection alone, at ~50%, suggesting that this protection originated from the prior infection and not from primary-series vaccination. This finding is also explained by the shortlived protection of primary-series vaccination against Omicron infections. 5, 37 However, the highest protection was that of hybrid immunity of prior infection and recent booster vaccination, at ~80%. This finding provides evidence for the benefit of vaccination, even for those with a prior infection. Strikingly, this protection is what one would expect if each of the prior-infection immunity and booster-vaccine immunity acted independently. Since prior infection reduced risk of infection by 50% and booster vaccination reduced it by 60%, the reduction in risk of infection for both combined, if they acted fully independently, is , that is an 80% reduction, just as observed in this study. This finding suggests that the combined effect of these two forms of immunity reflects neither synergy nor redundancy of their individual biological effects. Even though these five forms of immunity showed large differences in protection against symptomatic infection that ranged between 0-80%, remarkably, they all showed strong protection against COVID-19 hospitalization and death, at an effectiveness >70% (Figures 2-4 ). This suggests that any form of prior immunity, whether induced by prior infection or vaccination, is associated with strong and durable protection against COVID-19 hospitalization and death. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. There were no discernable differences in the effects of BNT162b2 versus mRNA-1273 vaccination. The results confirmed other findings that we reported recently including a protection of ~50% for prior infection against reinfection with BA.1, 3 a protection of ~50% for mRNA boosters relative to primary series, 6 and that mRNA vaccines have negligible effectiveness against Omicron several months after the second dose. 5, 39 This study has limitations. BA.1 and BA.2 ascertainment was based on proxy criteria, i.e., presence or absence of an S-gene "target failure" using the TaqPath PCR assay, but this method of ascertainment is well established not only for Omicron subvariants, but also for other variants such as Alpha. 19 ,40,41 Some Omicron infections may have been misclassified Delta infections, but this is not likely, as Delta incidence was limited during the study duration (Section S2). While matching was done for sex, age, and nationality, this was not possible for other factors, such as comorbidities, as such data are not available. However, matching by these factors provided demonstrable control of bias in studies of different epidemiologic designs and that used control groups in Qatar. 13, 14, 18, 28, 29 Effectiveness was assessed using an observational, testnegative, case-control, study design, rather than a design in which cohorts of individuals were followed up. However, the cohort study design applied earlier to the same population yielded findings similar to those of the test-negative case-control design, 17, 18, 42 supporting the validity of this standard approach in assessing immunity protection. 3,18,20-23 Moreover, our recent study of effectiveness of boosters relative to primary series used a cohort study design and generated results consistent with the above results. 6 Nonetheless, one cannot exclude the possibility that in real-world data, bias could arise in unexpected ways, or from unknown sources, such as subtle differences in test-seeking behavior or changes in the pattern of testing with introduction of other testing modalities, such as rapid All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. antigen testing (RAT). For example, with the large Omicron wave in Qatar, use of RAT was expanded to supplement PCR testing starting on January 5, 2022. However, RAT was broadly implemented and probably did not differentially affect PCR testing to introduce bias. With the small proportion of Qatar's population ≥50 years of age, 12 our findings may not be generalizable to other countries in which elderly citizens constitute a larger proportion of the population. Notwithstanding these limitations, findings were consistent with those of other studies for effectiveness against Omicron infection (with no BA.1/BA.2 subvariant specified). 37,43-47 Moreover, with the mass scale of PCR testing in Qatar, 14 the likelihood of bias is perhaps minimized. Extensive sensitivity and additional analyses were conducted to investigate effects of potential bias in our earlier studies that used similar methodology. These included different adjustments and controls in the analysis and different study inclusion and exclusion criteria, to investigate whether effectiveness estimates could have been biased. 14, 29 These analyses showed consistent findings. 3, 5, 14, 23, 29 In conclusion, there are no discernable differences in effects of prior infection, vaccination, and hybrid immunity against BA.1 and BA.2. Protection from prior infection with pre-Omicron variants is moderate and durable, but protection of primary-series vaccination is negligible several months after the second dose. Recent booster vaccination has moderate effectiveness, while hybrid immunity from prior infection and recent booster vaccination conferred the strongest protection at ~80%. All five forms of immunity were associated with strong and durable protection against COVID-19 hospitalization and death. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We acknowledge the many dedicated individuals at Hamad Medical Corporation, the Ministry of Public Health, the Primary Health Care Corporation, Qatar Biobank, Sidra Medicine, and Weill Cornell Medicine-Qatar for their diligent efforts and contributions to make this study possible. Statements made herein are solely the responsibility of the authors. HNA co-designed the study, performed the statistical analyses, and co-wrote the first draft of the article. HC co-designed the study, co-led the statistical analyses, and co-wrote the first draft of the article. LJA conceived and co-designed the study, co-led the statistical analyses, and co- All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Dr. Butt has received institutional grant funding from Gilead Sciences unrelated to the work presented in this paper. Otherwise, we declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 22, 2022. ; IQR denotes interquartile range, PCR polymerase chain reaction, and SMD standardized mean difference. * Cases and controls were exact-matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test. † SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates optimal balance in matching. ‡ SMD is for the mean difference between groups divided by the pooled standard deviation. subvariants in the BNT162b2-vaccine study. Cases and controls in studies of effectiveness against COVID-19 hospitalization and death were exact-matched one-to-five by sex, 10-year age group, nationality, and calendar week of PCR test. ** Severity, 10 criticality, 10 and fatality 11 were defined according to the World Health Organization guidelines. subvariants in the mRNA-1273-vaccine study. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Organization (WHO) classification as a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected person with "oxygen saturation of <90% on room air, and/or respiratory rate of >30 breaths/minute in adults and children >5 years old (or ≥60 breaths/minute in children <2 months old or ≥50 breaths/minute in children 2-11 months old or ≥40 breaths/minute in children 1-5 years old), and/or signs of severe respiratory distress (accessory muscle use and inability to complete full sentences, and, in children, very severe chest wall indrawing, grunting, central cyanosis, or presence of any other general danger signs)". 1 Detailed WHO criteria for classifying SARS-CoV-2 infection severity can be found in the WHO technical report. 1 Critical COVID-19 disease was defined per WHO classification as a SARS-CoV-2 infected person with "acute respiratory distress syndrome, sepsis, septic shock, or other conditions that would normally require the provision of life sustaining therapies such as mechanical ventilation (invasive or non-invasive) or vasopressor therapy". 1 Detailed WHO criteria for classifying SARS-CoV-2 infection criticality can be found in the WHO technical report. 1 COVID-19 death was defined per WHO classification as "a death resulting from a clinically compatible illness, in a probable or confirmed COVID-19 case, unless there is a clear alternative cause of death that cannot be related to COVID-19 disease (e.g. trauma). There should be no period of complete recovery from COVID-19 between illness and death. A death due to COVID-19 may not be attributed to another disease (e.g. cancer) and should be counted independently of preexisting conditions that are suspected of triggering a severe course of COVID-19". Detailed WHO criteria for classifying COVID-19 death can be found in the WHO technical report. 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Surveillance for SARS-CoV-2 variants in Qatar is mainly based on viral genome sequencing and multiplex RT-qPCR variant screening 3 of random positive clinical samples, 4-9 complemented by deep sequencing of wastewater samples. 6, 10 A total of 315 random SARS-CoV-2-positive specimens collected between December 19, 2021 and January 22, 2022 were viral whole-genome sequenced on a Nanopore GridION sequencing device. Of these, 300 (95.2%) were confirmed as Omicron infections and 15 (4.8%) as Delta All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The large Omicron-wave exponential-growth phase in Qatar started on December 19, 2021 and peaked in mid-January, 2022. 6, [12] [13] [14] [15] The study duration coincided with the intense Omicron wave where Delta incidence was limited. Accordingly, any PCR-positive test during the study duration, between December 23, 2021 and February 21, 2022, was assumed to be an Omicron infection. Of note that the study duration started on December 23, 2021, and not on December All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Informed by the viral genome sequencing and the RT-qPCR genotyping, a SARS-CoV-2 infection with the BA.1 subvariant was proxied as an S-gene "target failure" (SGTF) case using the TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific, USA) that tests for the S-gene and is affected by the del69/70 mutation in the S-gene. 16 A SARS-CoV-2 infection with the BA.2 subvariant was proxied as a non-SGTF case using this TaqPath Kit. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Effect of prior SARS-CoV-2 infection, BNT162b2 vaccination, mRNA-1273 vaccination, and hybrid immunity against symptomatic SARS-CoV-2 BA.1, BA.2, or any Omicron infection and against COVID-19 hospitalization and death. Special considerations related to Sex and gender The effectiveness estimates were derived by comparing cases (PCRpositive for Omicron) and controls (PCR-negative) with respect to prior infection and vaccination status. Cases and controls were exact-matched by sex to control for potential differences in the risk of exposure to SARS-CoV-2 infection by sex. Age Cases and controls were exact-matched by 10-year age group to control for potential differences in the risk of exposure to SARS-CoV-2 infection by age. Nonetheless, with the young population of Qatar, our findings may not be generalizable to other countries where elderly citizens constitute a larger proportion of the total population. Race or ethnicity group Cases and controls were exact-matched by nationality to control for potential differences in the risk of exposure to SARS-CoV-2 infection by nationality. Nationality is associated with race and ethnicity in the population of Qatar. Geography Cases and controls were exact-matched by nationality to control for potential differences in the risk of exposure to SARS-CoV-2 infection by nationality. Qatar has unusually diverse demographics in that 89% of the population are international expatriate residents coming from over 150 countries from all world regions. Individual-level data on co-morbid conditions were not available, but only a small proportion of the study population may have had serious comorbid conditions. Only 9% of the population of Qatar are ≥50 years of age (older age as proxy for co-morbidities). The national list of persons prioritized to receive the vaccine during the first phase of vaccine roll-out included only 19,800 individuals of all age groups with serious comorbid conditions. Overall representativeness of this study The study was based on the total population of Qatar and thus the study population is broadly representative of the diverse, by national background, but young and predominantly male, total population of Qatar. While there could be differences in the risk of exposure to SARS-CoV-2 infection by sex, age, and nationality, cases and controls were exact-matched by these factors to control for their potential impact on our estimates for effectiveness. Given that only 9% of the population of Qatar are ≥50 years of age and the limited proportion of the population with significant co-morbidities, our estimates of effectiveness may not be generalizable to other countries where elderly citizens constitute a larger proportion of the total population or where co-morbid conditions are prevalent. With the large Omicron wave, use of rapid antigen testing was expanded to supplement PCR testing starting from January 5, 2022, but reason for testing and symptoms were not available for analysis. However, use of rapid antigen testing may not have differentially affected the investigated cohorts as it was broadly implemented. COVID-19 denotes coronavirus disease 2019, PCR polymerase chain reaction, SARS-CoV-2 severe acute respiratory syndrome coronavirus 2. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Qatar viral genome sequencing data. Data on randomly collected samples Protection against the Omicron Variant from Previous SARS-CoV-2 Infection Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar Omicron (BA.1) and Sub-Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-based Computational Assessment Safety and Efficacy of the BNT162b2 mRNA Covid Efficacy and Safety of the mRNA-1273 SARS-CoV-2 World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death National Study Group for Covid Vaccination. Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar National Study Group for Covid Epidemiology. Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant National Study Group for Covid Vaccination. 132 (20.0) 2,132 (20.0) 2,556 (19.5) 2,556 (19.5) 30-39 years 937 * Cases and controls were exact-matched one-to-one by sex, 10-year age group, nationality, and calendar week of PCR test † SMD is the difference in the mean of a covariate between groups divided by the pooled standard deviation. An SMD<0.1 indicates optimal balance in matching ¶ These comprise 42 other nationalities in Qatar among cases and controls in the effectiveness against symptomatic BA.1 Omicron infection analysis, 63 other nationalities among cases and controls in the effectiveness against symptomatic BA.2 Omicron infection analysis, and 69 other nationalities among cases and controls in the effectiveness against any symptomatic Omicron infection analysis. References 1. World Health Organization. COVID-19 clinical management: living guidance Multiplexed RT-qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern V.3. dx Qatar viral genome sequencing data. Data on randomly collected samples One Year of SARS-CoV-2: Genomic Characterization of COVID-19 Outbreak in Qatar Real-Time SARS-CoV-2 Genotyping by High-Throughput Multiplex PCR Reveals the Epidemiology of the Variants of Concern in Qatar Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar Protection against the Omicron Variant from Previous SARS-CoV-2 Infection Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar SARS-CoV-2 variants of concern and variants under investigation in England: Technical briefing 34 The test-negative design for estimating influenza vaccine effectiveness Case-control vaccine effectiveness studies: Preparation, design, and enrollment of cases and controls Cases and controls in studies of effectiveness against COVID-19 hospitalization and death were exact-matched one-to-five by sex, 10-year age group, nationality, and calendar week of PCR test. ** Severity, 1 criticality, 1 and fatality 2 were defined according to the World Health Organization guidelines.All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.